Ocugen to detail 1-year OCU410 gene therapy data for geographic atrophy at ASRS
The presentation follows a 31% reduction in lesion growth reported at 12 months, and the ASRS talk will show whether that effect and safety hold at one year.
Executive Summary
- Ocugen will present 1-year follow-up data from its Phase 2 gene therapy trial in geographic atrophy at a major retina specialists conference, building on topline results already disclosed months earlier.
- The trial already showed a reduction in lesion growth at the higher doses with a favorable safety profile at 12 months, so the conference presentation is a maturation of a known effect rather than a first look.
- Geographic atrophy has approved chronic-dosing complement inhibitors but no approved gene therapy, and OCU410 is designed as a single-administration alternative, a distinction that matters for treatment burden if the effect holds at one year.
- The open question is whether the anatomic and functional gains reported at 12 months persist or extend at the 1-year mark, since durability past the initial readout is what would separate a single-dose approach from repeat-injection standards of care.
The presentation
Ocugen, Inc. said it will present 1-year ArMaDa results for OCU410 at the ASRS annual meeting in Montreal on July 17, 2026, with Arshad Khanani of Sierra Eye Associates delivering the primary presentation and Jay Chhablani of the University of Pittsburgh presenting a companion analysis of imaging and safety outcomes. The trial, registered as NCT06018558 and known by the acronym ArMaDa, is a Phase 1/2 study testing OCU410 delivered subretinally in adults with geographic atrophy, enrolling 63 participants under an anticipated target that has not changed since trial start. Ocugen+1Ocugen to Participate in Upcoming July Industry ConferencesJul 1, 2026Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What's already known
Ocugen disclosed topline 12-month ArMaDa results in March 2026 showing a statistically significant 31% reduction in geographic atrophy lesion growth at the medium and optimal OCU410 doses, alongside 27% preservation of the ellipsoid zone, a retinal layer marker of photoreceptor health, and no OCU410-related serious adverse events reported to date. The registered primary endpoints for the trial cover change in best-corrected visual acuity, low-luminance visual acuity, ocular anatomy by indirect ophthalmoscopy and slit-lamp exam, intraocular pressure, and the incidence of ocular and non-ocular adverse events, so the July presentation extends that safety and anatomic dataset to a longer follow-up window rather than introducing a new endpoint. No results have posted to the trial's ClinicalTrials.gov record, so the primary evidence for the 12-month finding sits in company disclosure rather than a completed registry results section. Ocugen+1Ocugen to Participate in Upcoming July Industry ConferencesJul 1, 2026Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558
Trial course
The study's primary completion date moved from an original March 2026 target to September 2025 in October 2023, then out again to February 2026 in May 2025, the same amendment that also reduced anticipated enrollment from 63 to 60 and shifted trial status from Recruiting to Active, not recruiting. The registry currently still lists the trial as Recruiting with the original 63-participant target, a status the platform has not yet reconciled with that later amendment. None of these date or enrollment movements rise to the level the operational model treats as a structural warning: the enrollment change sits at 0% against the model's significance threshold of 20% or more, a routine adjustment rather than a shortfall. NCT06018558Study to Assess the Safety and Efficacy of OCU410 for Geographic AtrophyNCT06018558
The competitive frame
Geographic atrophy has two approved complement inhibitors that require repeat injections, and gene therapy competitors in the space, including Gyroscope Therapeutics' GT005 and Genentech's OpRegen, use different mechanisms and delivery approaches. No trial in geographic atrophy shares OCU410's specific gene-replacement approach; the nearest comparators are modality precedents in gene therapy generally, run in other retinal and non-retinal diseases, which situates OCU410's mechanism as isolated within this indication rather than one of several programs testing the same biological hypothesis. A single-administration therapy that reproduces its 12-month anatomic and safety profile at one year would offer a treatment-burden alternative to chronic dosing in a disease where no gene therapy has reached approval.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.